4.6 Review

NF-κB Signaling in Ovarian Cancer

Journal

CANCERS
Volume 11, Issue 8, Pages -

Publisher

MDPI
DOI: 10.3390/cancers11081182

Keywords

nuclear factor-kappa B; RelA; RelB; stemness; chemoresistance; ovarian cancer

Categories

Funding

  1. Intramural Research Program, Center for Cancer Research, National Cancer Institute [ZIA BC 011054]

Ask authors/readers for more resources

The NF-kappa B signaling pathway is a master and commander in ovarian cancer (OC) that promotes chemoresistance, cancer stem cell maintenance, metastasis and immune evasion. Many signaling pathways are dysregulated in OC and can activate NF-kappa B signaling through canonical or non-canonical pathways which have both overlapping and distinct roles in tumor progression. The activation of canonical NF-kappa B signaling has been well established for anti-apoptotic and immunomodulatory functions in response to the tumor microenvironment and the non-canonical pathway in cancer stem cell maintenance and tumor re-initiation. NF-kappa B activity in OC cells helps to create an immune-evasive environment and to attract infiltrating immune cells with tumor-promoting phenotypes, which in turn, drive constitutive NF-kappa B activation in OC cells to promote cell survival and metastasis. For these reasons, NF-kappa B is an attractive target in OC, but current strategies are limited and broad inhibition of this major signaling pathway in normal physiological and immunological functions may produce unwanted side effects. There are some promising pre-clinical outcomes from developing research to target and inhibit NF-kappa B only in the tumor-reinitiating cancer cell population of OC and concurrently activate canonical NF-kappa B signaling in immune cells to promote anti-tumor immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells

Massimo Fantini, Justin M. David, Hing C. Wong, Christina M. Annunziata, Philip M. Arlen, Kwong Y. Tsang

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2019)

Article Oncology

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer Phase 1b Results From the JAVELIN Solid Tumor Trial

Mary L. Disis, Matthew H. Taylor, Karen Kelly, J. Thaddeus Beck, Michael Gordon, Kathleen M. Moore, Manish R. Patel, Jorge Chaves, Haeseong Park, Alain C. Mita, Erika P. Hamilton, Christina M. Annunziata, Hans Juergen Grote, Anja von Heydebreck, Jaspreet Grewal, Vikram Chand, James L. Gulley

JAMA ONCOLOGY (2019)

Meeting Abstract Oncology

Phase 1 with expansion cohorts in a study of NEO-201 in adults with chemo-resistant solid tumors.

Maria Pia Morelli, Justin M. David, Nicole D. Houston, Stan Lipkowitz, Jung-min Lee, Alexandra Dos Santos Zimmer, Farah Z. Zia, Irene Ekwede, Erin Nichols, Mira Pavelova, Rebecca Trupp, Stephen M. Hewitt, Massimo Fantini, Philip M. Arlen, Kwong Y. Tsang, Christina M. Annunziata

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses

Alexandra S. Zimmer, Erin Nichols, Ashley Cimino-Mathews, Cody Peer, Liang Cao, Min-Jung Lee, Elise C. Kohn, Christina M. Annunziata, Stanley Lipkowitz, Jane B. Trepel, Rajni Sharma, Lekha Mikkilineni, Margaret Gatti-Mays, William D. Figg, Nicole D. Houston, Jung-Min Lee

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Article Biochemistry & Molecular Biology

CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin

Yaowu He, Claire M. Davies, Brittney S. Harrington, Linh Hellmers, Yonghua Sheng, Amy Broomfield, Thomas McGann, Kate Bastick, Laurie Zhong, Andy Wu, Grace Maresh, Shannon McChesney, Kuan Yau Wong, Mark N. Adams, Ryan C. Sullivan, James S. Palmer, Lez J. Burke, Adam D. Ewing, Xin Zhang, David Margolin, Li Li, Rohan Lourie, Admire Matsika, Bhuvana Srinivasan, Michael A. McGuckin, John W. Lumley, John D. Hooper

ONCOGENE (2020)

Article Oncology

Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma

Tashbib Khan, Yaowu He, Thomas Kryza, Brittney S. Harrington, Jennifer H. Gunter, Mitchell A. Sullivan, Tahleesa Cuda, Rebecca Rogers, Claire M. Davies, Amy Broomfield, Madeline Gough, Andy C. Wu, Thomas McGann, S. John Weroha, Paul Haluska, Josephine M. Forbes, Jane E. Armes, Sinead C. Barry, Jermaine I. Coward, Nisha Jagasia, Naven Chetty, Cameron E. Snell, Rohan Lourie, Lewis C. Perrin, John D. Hooper

CANCERS (2020)

Article Oncology

Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model

Brittney S. Harrington, Michelle K. Ozaki, Michael W. Caminear, Lidia F. Hernandez, Elizabeth Jordan, Nicholas J. Kalinowski, Ian S. Goldlust, Rajarshi Guha, Marc Ferrer, Craig Thomas, Jyoti Shetty, Bao Tran, Nathan Wong, Carrie D. House, Christina M. Annunziata

CANCERS (2020)

Article Oncology

Matrix Drug Screen Identifies Synergistic Drug Combinations to Augment SMAC Mimetic Activity in Ovarian Cancer

Anne M. Noonan, Amanda Cousins, David Anderson, Kristen P. Zeligs, Kristen Bunch, Lidia Hernandez, Yusuke Shibuya, Ian S. Goldlust, Rajarshi Guha, Marc Ferrer, Craig J. Thomas, Christina M. Annunziata

CANCERS (2020)

Article Biochemistry & Molecular Biology

Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1

Thomas Kryza, Tashbib Khan, Scott Lovell, Brittney S. Harrington, Julia Yin, Sean Porazinski, Marina Pajic, Hannu Koistinen, Juha K. Rantala, Tobias Dreyer, Viktor Magdolen, Ute Reuning, Yaowu He, Edward W. Tate, John D. Hooper

Summary: The study identifies uPA as the master regulator of CDCP1 proteolysis, acting by directly cleaving CDCP1 and activating plasmin. Co-expression of uPA and CDCP1 predicts poor disease outcome in multiple cancers, and uPA-mediated CDCP1 proteolysis promotes metastasis in clinical models. These results suggest CDCP1 cleavage as a potential target for disrupting cancer, and establish sbABP technology as a novel approach for identifying disease-relevant proteases.

NATURE CHEMICAL BIOLOGY (2021)

Editorial Material Oncology

Prenatal DNA Sequencing for Fetal Aneuploidy Also Detects Maternal Cancer: Importance of Timely Workup and Management in Pregnant Women

Amy E. Turriff, Christina M. Annunziata, Diana W. Bianchi

JOURNAL OF CLINICAL ONCOLOGY (2022)

Review Oncology

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas

Kwong Yok Tsang, Massimo Fantini, Sharon A. Mavroukakis, Anjum Zaki, Christina M. Annunziata, Philip M. Arlen

Summary: This article describes a tumor-targeting monoclonal antibody called NEO-201, which can inhibit tumor growth through multiple mechanisms. NEO-201 kills tumor cells by engaging with immune cells through antibody-dependent cell-mediated cytotoxicity and complement dependent cytotoxicity, and it can also block interactions between tumor cells and other cells to enhance anti-cancer activity.

CANCERS (2022)

Article Oncology

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201

Kwong Y. Tsang, Massimo Fantini, Anjum Zaki, Sharon A. Mavroukakis, Maria Pia Morelli, Christina M. Annunziata, Philip M. Arlen

Summary: Glycosylation is an important post-translational modification that occurs on mammalian proteins and lipids. Disruption of O-glycosylation patterns, especially the truncation of O-glycans, has been observed in cancer cells. Monoclonal antibodies targeting truncated O-glycans in cancer cells can be an effective strategy to counter tumor growth.

CANCERS (2022)

Article Medicine, Research & Experimental

Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer

Brittney S. Harrington, Yaowu He, Tashbib Khan, Simon Puttick, Paul J. Conroy, Thomas Kryza, Tahleesa Cuda, Kamil A. Sokolowski, Brian W. C. Tse, Katherine K. Robbins, Buddhika J. Arachchige, Samantha J. Stehbens, Pamela M. Pollock, Sarah Reed, S. John Weroha, Paul Haluska, Carlos Salomon, Rohan Lourie, Lewis C. Perrin, Ruby H. P. Law, James C. Whisstock, John D. Hooper

THERANOSTICS (2020)

No Data Available